Compare FET & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FET | PRTC |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.0M | 464.3M |
| IPO Year | 2012 | N/A |
| Metric | FET | PRTC |
|---|---|---|
| Price | $43.79 | $18.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 173.2K | 3.2K |
| Earning Date | 02-19-2026 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $790,292,000.00 | $6,391,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.75 | N/A |
| P/E Ratio | ★ N/A | $8.98 |
| Revenue Growth | N/A | ★ 1265.60 |
| 52 Week Low | $12.78 | $13.30 |
| 52 Week High | $45.94 | $20.00 |
| Indicator | FET | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 66.17 | 56.32 |
| Support Level | $43.19 | $17.31 |
| Resistance Level | $45.65 | $19.08 |
| Average True Range (ATR) | 1.86 | 0.77 |
| MACD | 0.17 | 0.07 |
| Stochastic Oscillator | 70.33 | 61.77 |
Forum Energy Technologies Inc is a products company, serving the oil, natural gas, industrial and renewable energy industries. The company designs, manufactures, and distributes products and engages in aftermarket parts supply and services that complement its product offering. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. It operates in two reporting segments, namely Drilling and Completions and Artificial Lift and Downhole. Revenue largely comes from Artificial Lift and Downhole segment.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.